Besxar's Orbital Bet: A Chip Fab That Flies Home on a Booster
Besxar's first flight proved a canister can act like a cleanroom. The harder question is whether a fab that rides a reused booster can return enough wafers to matter.
Besxar's first flight proved a canister can act like a cleanroom. The harder question is whether a fab that rides a reused booster can return enough wafers to matter.
Resalis Therapeutics' RES-010, an antisense drug against microRNA-22, cleared a first-in-human safety test in 48 volunteers. The obesity thesis now hinges on Phase 1b body-composition data due in H1 2027.
Berkeley Lab counts about 2,061 GW of generation and storage seeking a connection, with only 13% of the 2000-2020 cohort built. Texas is testing a different model: classify large loads first, then audit them in December.
A twelve-year cargo-drone builder signs a Nasdaq SPAC at a ~$500M enterprise value. The filing shows an EU airline licence, 730+ aircraft under non-binding agreements and no meaningful revenue. The $25M floor decides the deal.
Qualcomm's first HBC silicon passed lab validation and the AI250 has taped out. Near-memory compute could cut inference's memory tax, but the 18x figure is vendor-estimated and four-layer yields remain unproven.
A 7-person startup turned a failed August print into the first rigid boom built in open space. The next test is a 5 kW solar array for orbital data centers, built where it will be used.
Cambridge spinout T-Therapeutics raised $133 million before either lead drug reached a patient. The bet is on OpTiMus, a platform of fully human T-cell receptors aimed at targets inside the cell.
ARENA is putting A$15 million into a 200-300 kW waste-heat electrolysis pilot at BOC's Hastings site in Victoria. Hadean's tubular solid-oxide design claims about 30% less electricity than conventional electrolysers. The demo will test that claim on real steelworks steam.